Actively Recruiting

Phase Not Applicable
Age: 55Years - 89Years
All Genders
NCT04171323

The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia

Led by University of Alabama at Birmingham · Updated on 2025-12-11

1305

Participants Needed

6

Research Sites

443 weeks

Total Duration

On this page

Sponsors

U

University of Alabama at Birmingham

Lead Sponsor

U

University of Florida

Collaborating Sponsor

AI-Summary

What this Trial Is About

Older adults at risk for dementia show a variety of cognitive deficits, which can be ameliorated by different cognitive training (CT) exercises. The best combination of CT exercises is unknown. The aim is to discover the most efficacious combination of CT exercises as compared to cognitive stimulation (which will serve as a stringent, active control) to modify the functional trajectories of older adults' with MCI, who are at high risk for dementia. The primary objective of the U01 phase was to design and pilot-test an adaptive, randomized clinical trial (RCT) of cognitive training (CT) combinations aimed to enhance performance of instrumental activities of daily living (IADL) among persons with mild cognitive impairment (MCI). In the R01 phase, the objective is to identify the best combination of CT exercises to delay dementia onset among persons with MCI. The longitudinal endpoint goal is reducing incident dementia. The primary aim of the study is to determine which CT combination has the best probability to delay dementia by producing the largest IADL improvements. The study further aims to explore neuroimaging and novel blood-based biomarkers.

CONDITIONS

Official Title

The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia

Who Can Participate

Age: 55Years - 89Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 55 to 89 years
  • Montreal Cognitive Assessment Score between 18 and 27 inclusive
  • History of some change in cognitive function and either a Clinical Dementia Rating (CDR) of 0.5 or CDR of 0 with a clinical diagnosis of mild cognitive impairment (MCI) based on evaluation
  • Stable dose for at least 30 days if using medications for dementia such as Namenda, Memantine, Donepezil, or others
  • Adequate hearing with thresholds less than or equal to 50 dB at 1000 and 2000 Hz in at least one ear
  • Adequate vision to read a computer screen with binocular visual acuity of 20/50 or better
  • Adequate motor skills to touch a computer screen or use a mouse
  • Willing and able to complete all study activities
  • Capable of providing informed consent
  • Ability to understand and comply with study procedures for the entire duration of the study
Not Eligible

You will not qualify if you...

  • Currently enrolled in another randomized clinical trial or research study assessing cognition
  • Diagnosis of dementia
  • Clinical Dementia Rating Scale of 1 or greater
  • History of large vessel stroke with significant residual motor or cognitive impairment
  • History of moderate to severe traumatic brain injury with lasting cognitive symptoms
  • History of brain tumor
  • Planned surgery requiring anesthesia, chemotherapy, or radiation in the six months after screening
  • Diagnosis of congestive heart failure
  • Primary diagnosis of idiopathic Parkinson's disease
  • Diagnosis of multiple sclerosis or amyotrophic lateral sclerosis (ALS)
  • Presence of non-neurodegenerative neurological disorders interfering with study activities
  • Unstable medical conditions causing cognitive fluctuations, such as unstable diabetes or oxygen-dependent COPD
  • Geriatric Depression Scale score greater than 5 out of 15 (treated and stable mood disorders with score less than 6 allowed)
  • Other clinically significant or unstable medical conditions that interfere with study participation
  • Previous participation in 10 or more hours of computerized cognitive intervention in past two years
  • Previous participation in cognitive intervention research at this site in past two years
  • Planning to be unavailable for more than three weeks in the six months following screening
  • Contraindications to MRI including pacemaker, metal implants, or claustrophobia

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 6 locations

1

University of California San Francisco

San Francisco, California, United States, 94158

Actively Recruiting

2

University of Florida

Gainesville, Florida, United States, 32611

Actively Recruiting

3

Active Mind Study

Tampa, Florida, United States, 33617

Actively Recruiting

4

University of Minnesota

Minneapolis, Minnesota, United States, 55455

Active, Not Recruiting

5

Clemson University

Greenville, South Carolina, United States, 29607

Actively Recruiting

6

Clemson University

Seneca, South Carolina, United States, 29672

Actively Recruiting

Loading map...

Research Team

J

Jerri Edwards, PhD

CONTACT

J

Jade Sutfin

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

5

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here